Tandem Diabetes Care Inc
NASDAQ:TNDM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tandem Diabetes Care Inc
Tax Provision
Tandem Diabetes Care Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Tax Provision
-$4.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Tax Provision
-$493m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-201%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Tax Provision
-$216.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-5%
|
|
|
Stryker Corp
NYSE:SYK
|
Tax Provision
-$1.3B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-16%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Tax Provision
-$1.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-17%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Tax Provision
-$434.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-10%
|
|
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.
See Also
What is Tandem Diabetes Care Inc's Tax Provision?
Tax Provision
-4.4m
USD
Based on the financial report for Dec 31, 2025, Tandem Diabetes Care Inc's Tax Provision amounts to -4.4m USD.
What is Tandem Diabetes Care Inc's Tax Provision growth rate?
Tax Provision CAGR 3Y
-38%
Over the last year, the Tax Provision growth was -7%. The average annual Tax Provision growth rates for Tandem Diabetes Care Inc have been -38% over the past three years .